Management of Diabetes, Hyperlipidemia, and Hypothyroidism in Hemodialysis Patients

Introduction to Management

The Kidney International guidelines recommend that glycemic control in hemodialysis patients should focus on insulin therapy as first-line, with consideration of a GLP-1 receptor agonist if additional glucose lowering is needed, and aggressive statin therapy must be initiated immediately for severe hyperlipidemia, while thyroid replacement must be optimized as hypothyroidism significantly worsens both lipid abnormalities and cardiovascular risk 1, 2, 3

Insulin therapy is the cornerstone for patients on dialysis, as most oral agents have significant limitations at this stage of kidney disease, and the target HbA1c should be individualized between 7.0-7.5% for dialysis patients, balancing glycemic control against hypoglycemia risk 3, 5
Consider adding a long-acting GLP-1 receptor agonist if insulin alone is insufficient, as these agents can be used safely down to eGFR 15 and provide cardiovascular protection, according to the Annals of Internal Medicine 4, 6, 5

Initiate high-intensity statin therapy immediately for all patients with diabetes and CKD, regardless of baseline LDL levels, as recommended by the Kidney International guidelines 1, 2, 3, 5
Add ezetimibe 10 mg daily if LDL remains >70 mg/dL on statin therapy, as it provides additional LDL reduction without significant adverse effects in CKD, and consider PCSK9 inhibitors if LDL remains elevated despite statin plus ezetimibe 1, 2

Target blood pressure should be <130/80 mmHg, though this must be balanced against intradialytic hypotension risk, and aspirin 81 mg daily should be used for secondary prevention if the patient has established cardiovascular disease, as recommended by the Kidney International guidelines 1, 2, 7

Protein intake should be 1.0-1.2 g/kg/day for hemodialysis patients to offset dialysis-related protein losses and prevent malnutrition, and emphasize a diet high in vegetables, fruits, whole grains, fiber, legumes, plant-based proteins, unsaturated fats, and nuts, while limiting processed meats, refined carbohydrates, and sweetened beverages, according to the Annals of Internal Medicine 8, 5
Recommend at least 150 minutes per week of moderate-intensity physical activity, adjusted to the patient's cardiovascular and physical tolerance, as physical activity improves cardiovascular health, glycemic control, and quality of life even in dialysis patients 4, 6, 8, 3

Regular reassessment every 3 months is essential for dialysis patients with diabetes, including HbA1c every 3 months to assess glycemic control, lipid panel every 3 months initially after starting or adjusting lipid-lowering therapy, then every 6 months once stable, and potassium, phosphorus, calcium, and PTH as per KDIGO CKD-MBD guidelines 1, 2, 3, 5